Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins

Research output: Contribution to journalReviewResearchpeer-review

Standard

Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins. / Dams, Dorien; Brøndsted, Lone; Drulis-Kawa, Zuzanna; Briers, Yves.

In: Biochemical Society Transactions, Vol. 47, No. 1, 2019, p. 449-460.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Dams, D, Brøndsted, L, Drulis-Kawa, Z & Briers, Y 2019, 'Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins', Biochemical Society Transactions, vol. 47, no. 1, pp. 449-460. https://doi.org/10.1042/BST20180172

APA

Dams, D., Brøndsted, L., Drulis-Kawa, Z., & Briers, Y. (2019). Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins. Biochemical Society Transactions, 47(1), 449-460. https://doi.org/10.1042/BST20180172

Vancouver

Dams D, Brøndsted L, Drulis-Kawa Z, Briers Y. Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins. Biochemical Society Transactions. 2019;47(1):449-460. https://doi.org/10.1042/BST20180172

Author

Dams, Dorien ; Brøndsted, Lone ; Drulis-Kawa, Zuzanna ; Briers, Yves. / Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins. In: Biochemical Society Transactions. 2019 ; Vol. 47, No. 1. pp. 449-460.

Bibtex

@article{f02d02a3f7ea443e838cda44a440d1ad,
title = "Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins",
abstract = "Bacteriophages and phage tail-like bacteriocins (PTLBs) rely on receptor-binding proteins (RBPs) located in tail fibers or spikes for an initial and specific interaction with susceptible bacteria. Bacteriophages kill bacteria through a lytic, replicative cycle, whereas PTLBs kill the target through membrane depolarization in a single hit mechanism. Extensive efforts in the engineering of RBPs of both phages and PTLBs have been undertaken to obtain a greater understanding of the structural organization of RBPs. In addition, a major goal of engineering RBPs of phages and PTLBs is the production of antibacterials with a customized spectrum. Swapping of the RBP of phages and PTLBs results in a shift in activity spectrum in accordance with the spectrum of the new RBP. The engineering of strictly virulent phages with new RBPs required significant technical advances in the past decades, whereas the engineering of RBPs of PTLBs relied on the traditional molecular techniques used for the manipulation of bacteria and was thus relatively straightforward. While phages and PTLBs share their potential for specificity tuning, specific features of phages such as their lytic killing mechanism, their self-replicative nature and thus different pharmacokinetics and their potential to co-evolve are clear differentiators compared with PTLBs in terms of their antibacterial use.",
author = "Dorien Dams and Lone Br{\o}ndsted and Zuzanna Drulis-Kawa and Yves Briers",
year = "2019",
doi = "10.1042/BST20180172",
language = "English",
volume = "47",
pages = "449--460",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins

AU - Dams, Dorien

AU - Brøndsted, Lone

AU - Drulis-Kawa, Zuzanna

AU - Briers, Yves

PY - 2019

Y1 - 2019

N2 - Bacteriophages and phage tail-like bacteriocins (PTLBs) rely on receptor-binding proteins (RBPs) located in tail fibers or spikes for an initial and specific interaction with susceptible bacteria. Bacteriophages kill bacteria through a lytic, replicative cycle, whereas PTLBs kill the target through membrane depolarization in a single hit mechanism. Extensive efforts in the engineering of RBPs of both phages and PTLBs have been undertaken to obtain a greater understanding of the structural organization of RBPs. In addition, a major goal of engineering RBPs of phages and PTLBs is the production of antibacterials with a customized spectrum. Swapping of the RBP of phages and PTLBs results in a shift in activity spectrum in accordance with the spectrum of the new RBP. The engineering of strictly virulent phages with new RBPs required significant technical advances in the past decades, whereas the engineering of RBPs of PTLBs relied on the traditional molecular techniques used for the manipulation of bacteria and was thus relatively straightforward. While phages and PTLBs share their potential for specificity tuning, specific features of phages such as their lytic killing mechanism, their self-replicative nature and thus different pharmacokinetics and their potential to co-evolve are clear differentiators compared with PTLBs in terms of their antibacterial use.

AB - Bacteriophages and phage tail-like bacteriocins (PTLBs) rely on receptor-binding proteins (RBPs) located in tail fibers or spikes for an initial and specific interaction with susceptible bacteria. Bacteriophages kill bacteria through a lytic, replicative cycle, whereas PTLBs kill the target through membrane depolarization in a single hit mechanism. Extensive efforts in the engineering of RBPs of both phages and PTLBs have been undertaken to obtain a greater understanding of the structural organization of RBPs. In addition, a major goal of engineering RBPs of phages and PTLBs is the production of antibacterials with a customized spectrum. Swapping of the RBP of phages and PTLBs results in a shift in activity spectrum in accordance with the spectrum of the new RBP. The engineering of strictly virulent phages with new RBPs required significant technical advances in the past decades, whereas the engineering of RBPs of PTLBs relied on the traditional molecular techniques used for the manipulation of bacteria and was thus relatively straightforward. While phages and PTLBs share their potential for specificity tuning, specific features of phages such as their lytic killing mechanism, their self-replicative nature and thus different pharmacokinetics and their potential to co-evolve are clear differentiators compared with PTLBs in terms of their antibacterial use.

U2 - 10.1042/BST20180172

DO - 10.1042/BST20180172

M3 - Review

C2 - 30783013

AN - SCOPUS:85062529513

VL - 47

SP - 449

EP - 460

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 1

ER -

ID: 217111020